HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G Widens Pricing Strategy To At Least 60% Of Products As Costs Soar

Executive Summary

Procter & Gamble’s pricing strategy now impacts 10 of its US product categories, with action also being taken broadly in non-US markets. President and CEO Jon Moeller calls this pricing "at a different level" historically speaking, and warns there will be ‘bumps in the road." But P&G is confident in its long track record and raises full-year guidance accordingly.

You may also be interested in...



Consumer Elasticity Exceeds P&G Expectations

With high consumer elasticity not expected to last, P&G adapted to price sensitivity by offering “price levers across brands,” says CFO Andre Schulten  A strong cough/cold season drove 50% organic sales growth in personal health care products in North America.

China Lockdown Offsets P&G Sales Growth Across Product Categories In All Other Regions

Soaring beauty sales in North America, Europe and Latin America were offset by double-digit decline in greater China due to COVID-19 lockdowns. To offset supply chain problems, firm plans to invest in manufacturing in North America and Europe.

US Q1 Consumer Health Earnings Preview: Pivoting From Planning Changes To Parsing Results

Inflation's impact on consumer spending will be front and center in sector’s quarterly reports, beginning with J&J on 19 April. Potential impact also from price hikes common from most firms since early 2021 in response to increasing costs. Russia’s invasion of Ukraine also will prompt comment.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS152127

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel